RayzeBio Investor Relations Material
Latest events
Q3 2023
13 Nov, 2023
Corporate Presentation
12 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RayzeBio Inc
Access all reports
RayzeBio Inc is a biotechnology firm concentrated on developing radiopharmaceutical therapeutics (RPT) for cancer treatment. Their leading drug candidate, RYZ101, is in clinical trials aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, RayzeBio is working on RYZ801, a novel proprietary peptide targeting GPC3 for the treatment of hepatocellular carcinoma (HCC), among other innovative drug candidates targeting various cancers. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
RYZB
Country
🇺🇸 United States